Found 23 articles
Oncolytic Virus Cancer Immunotherapy Market Companies Clinical Trials Insight 2028
Global Oncolytic Virus Immunotherapy Market and Clinical Trials Insight 2028 Report Overview:
Vyriad, Inc. Appoints Scott Beck as Chief Operating Officer
Vyriad, Inc., a biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announces the appointment of Scott Beck, MBA as Chief Operating Officer.
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
Vyriad, Inc. announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc. with participation from existing investors.
Oral Vaccine Boosts COVID Immunity
Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2.
Vyriad, Inc. Appoints Harry Hoffman To Its Board Of Directors
Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, announced the appointment of leading life sciences investor Harry Hoffman to the Company's board of directors.
Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies
Imanis Life Sciences (“Imanis” or “The Company”), in collaboration with Vyriad, Inc. and Regeneron, today announced data from its latest improvedIMMUNO-COVTM test, an assay for the quantitative measure of SARS-CoV-2 (COVID-19) neutralizing antibodies.
Sales Revenue in the Oncolytic Virus Immunotherapy Market to Witness Growth at Robust CAGR 12% During 2019 to 2029
The new study report by Persistence Market Research (PMR) reveals that the oncolytic virus immunotherapy market value is all set to reach US$ ~67 Mn, by 2019-end. As per the PMR’s report, the oncolytic virus immunotherapy market is estimated to grow at a CAGR of ~12% over the period of assessment, 2019-2029.
Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2019 and provided a business update.
Big Pharma Gaining Increased Interest in Fighting Cancer With Oncolytic Virus Therapies
USA News Group – As the global oncology drug market is projected to grow at a rate of 7.6% CAGR to hit $176.5 billion by 2025, there's a growing interest within the big pharma sector to tap into the power of viruses to fight cancer.
Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer
Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments
Targovax is Invited to Present at Upcoming 2018 Investor and Industry Conferences
Targovax ASA announces that members of its senior management will present at the following life sciences and investor conferences
Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Oncolytic Virus, Voyager-V1, in Combination with Anti-PD-L1 Antibody, Avelumab, in Phase 1 Clinical Study for Metastatic Colorectal Cancer
Voyager-V1 is being administered to inflame the tumors, and avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.
Although it may be almost heresy to say it to venture capitalists and many research scientists, there are other places in the U.S. to form biotech companies than San Francisco and Boston.
Vyriad, based in Rochester, Minnesota, announced it is building out its facility in 25,000 square feet of space it is leasing on the IBM Campus in Rochester.
Vyriad to Build State-of-the-Art Facility for Manufacturing Oncolytic Virus Anti-Cancer Vaccines in Rochester, Minn.
Vyriad announced today the signing of a contract to build out its facility in 25,000 square feet of leased space on the IBM Campus in Rochester, Minnesota.
Biotech Startup Vyriad Graduates from Mayo Clinic Incubator to Larger Space
Profectus BioSciences, Inc. Bivalent Vaccine Protects Animals From Infection And Death After Exposure To Chikungunya Or Zika Virus
Vyriad Appoints Alvin E. Mcquinn To Board Of Directors
Vyriad Announces Agreement With Imanis Life Sciences For Development Of Theranostic Tests To Predict Responsiveness To Oncolytic Virotherapy